

SANGAMO BIOSCIENCES INC  
 Form 4  
 May 17, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 LANPHIER EDWARD O II

2. Issuer Name and Ticker or Trading Symbol  
 SANGAMO BIOSCIENCES INC  
 [SGMO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 05/15/2007

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Pres and Chief Ex Officer

C/O SANGAMO BIOSCIENCES, INC. STE: 100A, POINT RICHMOND TECH CNTR, 501 CANAL BL

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RICHMOND, CA 94804

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code V	Amount		
Common Stock	05/15/2007		S <sup>(1)</sup>	D	500	\$ 6.71	1,863,492 I By Trust <sup>(2)</sup>
Common Stock	05/15/2007		S <sup>(1)</sup>	D	1,500	\$ 6.72	1,861,992 I By Trust <sup>(2)</sup>
Common Stock	05/15/2007		S <sup>(1)</sup>	D	600	\$ 6.73	1,861,392 I By Trust <sup>(2)</sup>
Common Stock	05/15/2007		S <sup>(1)</sup>	D	2,600	\$ 6.75	1,858,792 I By Trust <sup>(2)</sup>

Edgar Filing: SANGAMO BIOSCIENCES INC - Form 4

Common Stock	05/15/2007	S <sup>(1)</sup>	1,400	D	\$ 6.76	1,857,392	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	7,700	D	\$ 6.8	1,849,692	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	10,000	D	\$ 6.82	1,839,692	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	300	D	\$ 6.87	1,839,392	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	100	D	\$ 6.88	1,839,292	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	200	D	\$ 6.89	1,839,092	I	By Trust <sup>(2)</sup>
Common Stock	05/15/2007	S <sup>(1)</sup>	100	D	\$ 6.9	1,838,992	I	By Trust <sup>(2)</sup>
Common Stock						200,000	D	
Common Stock						100,000	I	By Trust for Son <sup>(3)</sup>
Common Stock						100,000	I	By Trust for Daughter <sup>(3)</sup>
Common Stock						100,000	I	By Trust for Daughter <sup>(3)</sup>
Common Stock						100,000	I	By Trust for Daughter <sup>(3)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu... Deriv... Secur... Bene... Own... Follo...
--------------------------------------------	--------------------------------------------------------	--------------------------------------	----------------------------------------------------	--------------------------------	---------------------------------------------	----------------------------------------------------------	---------------------------------------------------------------	--------------------------------------------	----------------------------------------------------

(A) or  
 Disposed  
 of (D)  
 (Instr. 3,  
 4, and 5)

Repor  
 Trans  
 (Instr

Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
------	---	-----	-----	---------------------	--------------------	-------	----------------------------------------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LANPHIER EDWARD O II C/O SANGAMO BIOSCIENCES, INC. STE: 100A POINT RICHMOND TECH CNTR, 501 CANAL BL RICHMOND, CA 94804	X		Pres and Chief Ex Officer	

## Signatures

/s/ Edward O.  
 Lanphier, II

05/17/2007

\_\_Signature of Reporting  
 Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2006.
- (2) These shares are held in the Edward O. Lanphier II and Cameron M. Lanphier Trust U/T/A August 30, 2002, Edward O. Lanphier II and Cameron M. Lanphier, Trustees.
- (3) Reporting Person disclaims beneficial ownership of the shares held by each of his children and this report shall not be deemed to be an admission that Mr. Lanphier is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.